$ARTH
Arch Therapeutics, Inc.

2016 Q3 Form 10-Q Financial Statement

#000114420416115040 Filed on July 28, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.340M $1.290M $810.0K
YoY Change 15.52% 59.26% -2.41%
% of Gross Profit
Research & Development $440.0K $438.6K $525.1K
YoY Change 2.33% -16.47% 63.92%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $1.780M $1.733M $1.338M
YoY Change 11.25% 29.48% 16.74%
Operating Profit -$1.733M -$1.338M
YoY Change 29.48% 16.74%
Interest Expense -$30.00K $33.10K $134.3K
YoY Change -107.32% -75.36% 383.83%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.820M -$1.770M -$770.0K
YoY Change 65.45% 129.87% -287.8%
Income Tax
% Of Pretax Income
Net Earnings -$1.820M -$1.766M -$772.4K
YoY Change 65.45% 128.61% -288.04%
Net Earnings / Revenue
Basic Earnings Per Share -$0.02
Diluted Earnings Per Share -$12.40K -$14.63K -$0.02
COMMON SHARES
Basic Shares Outstanding 134.2M shares 76.80M shares
Diluted Shares Outstanding 76.80M shares

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.040M $5.750M $3.270M
YoY Change 27.27% 75.84% 81.67%
Cash & Equivalents $5.036M $3.274M
Short-Term Investments
Other Short-Term Assets $110.0K $160.0K $40.00K
YoY Change 175.0% 300.0% 33.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.144M $5.900M $3.320M
YoY Change 28.51% 77.71% 80.95%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $5.144M $5.900M $3.320M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $5.144M $5.900M $3.320M
YoY Change 28.51% 77.71% 80.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $374.9K $490.0K $500.0K
YoY Change 61.76% -2.0% 201.18%
Accrued Expenses $600.0K $190.0K $480.0K
YoY Change 140.0% -60.42% 118.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $900.0K $0.00 $500.0K
YoY Change 91.49% -100.0%
Total Short-Term Liabilities $1.879M $680.0K $1.890M
YoY Change 46.09% -64.02% -45.38%
LONG-TERM LIABILITIES
Long-Term Debt $80.00K $980.0K $960.0K
YoY Change -91.75% 2.08% 1.05%
Other Long-Term Liabilities $30.00K $300.0K $6.530M
YoY Change -85.71% -95.41% 22.74%
Total Long-Term Liabilities $104.5K $1.280M $1.147M
YoY Change -91.12% 11.64% -81.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.879M $680.0K $1.890M
Total Long-Term Liabilities $104.5K $1.280M $1.147M
Total Liabilities $1.983M $1.960M $3.038M
YoY Change -19.47% -35.49% -68.78%
SHAREHOLDERS EQUITY
Retained Earnings -$21.71M -$14.00M
YoY Change 38.11%
Common Stock $24.88M $14.38M
YoY Change 44.1% 19873.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.161M $3.940M $279.4K
YoY Change
Total Liabilities & Shareholders Equity $5.144M $5.900M $3.318M
YoY Change 28.51% 77.83% 80.84%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$1.820M -$1.766M -$772.4K
YoY Change 65.45% 128.61% -288.04%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$1.090M -$1.330M -$820.0K
YoY Change -32.3% 62.2% 10.81%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 370.0K 5.410M 3.520M
YoY Change -83.91% 53.69% -3620.0%
NET CHANGE
Cash From Operating Activities -1.090M -1.330M -820.0K
Cash From Investing Activities
Cash From Financing Activities 370.0K 5.410M 3.520M
Net Change In Cash -720.0K 4.080M 2.700M
YoY Change -204.35% 51.11% -421.43%
FREE CASH FLOW
Cash From Operating Activities -$1.090M -$1.330M -$820.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 arth Gain On Exercise Of Warrants
GainOnExerciseOfWarrants
75321 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-8625 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-996813 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
CY2015Q2 us-gaap Revenues
Revenues
0 USD
CY2016Q2 us-gaap Revenues
Revenues
0 USD
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
813122 USD
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1294050 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
525107 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
438627 USD
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
1338229 USD
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
1732677 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1338229 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1732677 USD
CY2015Q2 us-gaap Interest Expense
InterestExpense
134326 USD
CY2016Q2 us-gaap Interest Expense
InterestExpense
33104 USD
CY2015Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-302524 USD
CY2016Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
0 USD
CY2015Q2 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
565844 USD
CY2016Q2 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-33104 USD
CY2016Q2 arth Gain On Exercise Of Warrants
GainOnExerciseOfWarrants
0 USD
CY2015Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
927373 USD
CY2016Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-772385 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-1765781 USD
us-gaap Net Income Loss
NetIncomeLoss
-4175491 USD
us-gaap Net Income Loss
NetIncomeLoss
-1227206 USD
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
120999849 shares
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
76804674 shares
arth Change To Gain Or Loss On Warrant Modification
ChangeToGainOrLossOnWarrantModification
-996813 USD
arth Change To Gain Or Loss On Warrant Modification
ChangeToGainOrLossOnWarrantModification
0 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
644900 USD
us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-52500 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
CY2014Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
224000 USD
CY2015Q1 arth Gain Loss On Warrant Derivative Modification
GainLossOnWarrantDerivativeModification
624016 USD
CY2016Q2 us-gaap Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral
DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral
354988 USD
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
395012 USD
CY2016Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
0 USD
CY2015Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
605000 USD
CY2013Q2 arth Increase In Aggregate Number Of Shares
IncreaseInAggregateNumberOfShares
3000000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9438 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.1944 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0052 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.024 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10776500 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2785000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
362500 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
426040 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12772960 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
10829562 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
12772960 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.3
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.39
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.19
arth Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedWeightedAverageRemainingContractualTerm
P0Y
arth Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm
P0Y
arth Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
P0Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M7D
arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
P4Y11M8D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y3M7D
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
arth Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedAggregateIntrinsicValue
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
arth Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodAggregateIntrinsicValue
0 USD
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5429881 USD
arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue
4084799 USD
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
5429881 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.36
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.32
arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
0.31
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.32
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
Arch Therapeutics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001537561
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
ARTH
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
134207348 shares
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
133024279 shares
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
133024279 shares
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
107592205 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
107592205 shares
arth Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
3388919 USD
arth Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
3066000 USD
arth Issuance Of Inducement Of Shares
IssuanceOfInducementOfShares
0 USD
arth Issuance Of Inducement Of Shares
IssuanceOfInducementOfShares
100050 USD
arth Reclassificationofseriesaandcwarrantsfromderivativeliabilitiestoequity
Reclassificationofseriesaandcwarrantsfromderivativeliabilitiestoequity
0 USD
arth Reclassificationofseriesaandcwarrantsfromderivativeliabilitiestoequity
Reclassificationofseriesaandcwarrantsfromderivativeliabilitiestoequity
3263753 USD
arth Financing Costs On Issuance Of Common Stock And Warrants
FinancingCostsOnIssuanceOfCommonStockAndWarrants
333320 USD
arth Financing Costs On Issuance Of Common Stock And Warrants
FinancingCostsOnIssuanceOfCommonStockAndWarrants
150000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Use of Estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Concentration of Credit Risk</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q2 us-gaap Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity
EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity
3263753 USD
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P0Y
CY2016Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
2765 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
8294 USD
CY2016Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
975118 USD
CY2015Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
966824 USD
CY2015Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
2765 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
8294 USD

Files In Submission

Name View Source Status
0001144204-16-115040-index-headers.html Edgar Link pending
0001144204-16-115040-index.html Edgar Link pending
0001144204-16-115040.txt Edgar Link pending
0001144204-16-115040-xbrl.zip Edgar Link pending
arth-20160630.xml Edgar Link completed
arth-20160630.xsd Edgar Link pending
arth-20160630_cal.xml Edgar Link unprocessable
arth-20160630_def.xml Edgar Link unprocessable
arth-20160630_lab.xml Edgar Link unprocessable
arth-20160630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v444768_10q.htm Edgar Link pending
v444768_ex31-1.htm Edgar Link pending
v444768_ex31-2.htm Edgar Link pending
v444768_ex32-1.htm Edgar Link pending